Grand Rounds in Urology: CME & Educational Resources for Urology Professionals

Since its founding, Grand Rounds in Urology has been a premier hub of quality, cutting-edge knowledge for professionals in the field of urology. Now we are proud to offer CME-accredited online courses from top faculty.

Learn More

Overview This course, Innovations: Urologic Oncology, features presentations from world-class experts in urology recorded for the 25th Annual Innovations in Urologic Practice conference, held September 26, 2020. This program provides a detailed review and commentary on multiple key issues in the area of urologic oncology. Among the featured oncological topics are a description of bladder cancer and immunotherapies, as well as upper tract cancer management and prostate cancer, including discussions about state-of-the-art imaging, focal therapy, and MRI. Experts will also discuss new tools and techniques for nephrectomy and treating advanced renal cell carcinoma.  Target Audience This activity is designed for urologists, medical oncologists, radiation oncologists, primary care specialists, and other healthcare professionals involved in the diagnosis and management of urologic diseases. Faculty Chair: Michael Coburn, MD, FACS Professor of Urology Baylor College of Medicine Houston, Texas Moderators: A. Edward Yen, MD, Baylor College of Medicine Jennifer M. Taylor, MD, Baylor College of Medicine Faculty: Michael A. Brooks, MD, Baylor College of Medicine E. David Crawford, MD, University of California, San Diego Guilherme Godoy, MD, Baylor College of Medicine Jennifer M. Taylor, MD, Baylor College of Medicine Seth P. Lerner, MD, Baylor College of Medicine Richard E. Link, MD, PhD, Baylor College of Medicine A. Edward Yen, MD, Baylor College of Medicine Wesley A. Mayer, Baylor College of Medicine   Accreditation This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Carden Jennings Publishing, Co., Ltd. MER is accredited by ACCME to provide continuing medical education for physicians. Medical Education Resources designates this live, online activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been accredited by Medical Education Resources for the following dates: Start date: 12/18/2020 End date: 12/18/2021 Format: enduring webcast This activity has been developed and is intended and designed for primary care physicians, urologists, and other healthcare providers involved in the treatment of patients with upper tract urothelial carcinoma. Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. MER Policies on Commercial Support and Conflict of Interest Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest. This activity is jointly provided by Medical Education Resources and Carden Jennings Publishing Co., Ltd. Individual disclosures are provided below.  Potential conflicts have been resolved through MER’s content review process. The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: Michael A. Brooks, MD No financial relationships to disclose Michael Coburn, MD, FACS No financial relationships to disclose Guilherme Godoy, MD, MPH No financial relationships to disclose      Richard E. Link, MD, PhD No financial relationships to disclose  A. Edward Yen, MD No financial relationships to disclose E. David Crawford, MD Speakers bureau membership and advisory committee membership (Pfizer/Astellas, Janssen, and Ferring) Board membership and ownership interests (3D Bx) Ownership interests (Precision BX) Speakers bureau membership (Bayer, Genomic Health, and Tolmar) Speakers bureau membership and consultancy (MDx)  Wife is a consultant (Microgren DX), Consultancy and honorarium recipient (Carden Jennings Publishing)       Seth P. Lerner, MD Research support from ENDO, FKD, UroGen, and Viventia Advisory committee membership and consultancy (Anchiano Therapeutics and UroGen)  Advisory committee membership (QED, Genentech, and Ferring) Consultancy (Vaxxion) Honorarium recipient (Nucleix and Dava Oncology)    Jennifer M. Taylor, MD, MPH Research support from Photocure, maker of Cysview (principal investigator) Honorarium recipient (Medscape WebMD)  The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: Carden Jennings Publishing - No financial relationships to disclose MER content managers - No financial relationships to disclose How to Complete the Course and Obtain CME Credit This course is divided into two sections: Ten Presentations Post-Activity Survey There will be a pre-course CME registration. Once that has been completed, select “Click Here to Continue” to advance to the lectures. After watching the entire video, select “Click Here to Continue” to advance to the next lecture until you have watched all ten. The post-activity survey is a self-evaluation consisting of several multiple-choice and feedback questions. Once the post-activity survey has been completed, select “Click Here to Continue,” and you will be redirected to the course page, where the option to “Print Your Certificate” will be available. You will also receive an email with the CME Certificate attached once the course is completed.   Read More

Overview This course, Innovations: Men’s Health, features presentations from world-class experts in urology recorded for the 25th Annual Innovations in Urologic Practice conference, held September 26, 2020. This program provides a detailed review and commentary on multiple key issues in the area of men’s health. Topics covered include priapism, optimization of erectile function following radical prostatectomy, genital reconstruction, male infertility, management of incontinence, management of urethral strictures, and renal transplantation, among others. Target Audience: This activity is designed for urologists, medical oncologists, radiation oncologists, primary care specialists, and other healthcare professionals involved in the diagnosis and management of urologic diseases. Faculty: Chair and Moderator: Mohit Khera, MD, MBA, MPH  Professor of Urology, Baylor College of Medicine  Houston, Texas Moderator: Wesley A. Mayer, MD, Baylor College of Medicine Faculty: Michael Coburn, MD, FACS, Baylor College of Medicine Brian S. Christine, MD, Urology Centers of Alabama Larry I. Lipshultz, MD, Baylor College of Medicine Maxx A. Gallegos, MD, University of New Mexico Alexander Gomelsky, MD, LSU Health Shreveport Wesley A. Mayer, MD, Baylor College of Medicine Accreditation This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Carden Jennings Publishing, Co., Ltd. MER is accredited by ACCME to provide continuing medical education for physicians. Medical Education Resources designates this live, online activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been accredited by Medical Education Resources for the following dates: Start date: 12/18/2020 End date: 12/18/2021 Format: enduring webcast This activity has been developed and is intended and designed for primary care physicians, urologists, and other healthcare providers involved in the treatment of patients with upper tract urothelial carcinoma. Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physician Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Carden Jennings Publishing, Co., Ltd. MER Policies on Commercial Support and Conflict of Interest Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest. This activity is jointly provided by Medical Education Resources and Carden Jennings Publishing Co., Ltd. Individual disclosures are provided below.  Potential conflicts have been resolved through MER’s content review process. The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: Michael Coburn, MD, FACS  No financial relationships to disclose       Maxx A. Gallegos, MD No financial relationships to disclose Alexander Gomelsky, MD No financial relationships to disclose Wesley A. Mayer, MD No financial relationships to disclose    Brian S. Christine, MD Advisory committee membership and consultancy (Boston Scientific Corp) Consultancy (Coloplast Corp) Mohit Khera, MD, MBA, MPH Speaker bureau membership, advisory committee membership, and honorarium recipient (Auxilium and Lily) Advisory committee membership and honorarium recipient (Merck and MEDA)  Consultancy and honorarium recipient (AMS)      Larry I. Lipschultz, MD Speakers Bureau Membership (American Medical Systems)  Speakers Bureau Membership and consultancy (Endo Pharmaceuticals) Consultancy (Aytu Bioscience, AbbVie, Lipocine and Clarus Therapeutics) Advisory committee membership (Vault Health)  Ownership interests (Augmenta LLC)  The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: Carden Jennings Publishing No financial relationships to disclose MER content managers No financial relationships to disclose How to Complete the Course and Obtain CME Credit This course is divided into two sections: Eight Presentations Post-Activity Survey There will be a pre-course CME registration. Once that has been completed, select “Click Here to Continue” to advance to the lectures. After watching the entire video, select “Click Here to Continue” to advance to the next lecture until you have watched all eight. The post-activity survey is a self-evaluation consisting of several multiple-choice and feedback questions. Once the post-activity survey has been completed, select “Click Here to Continue,” and you will be redirected to the course page, where the option to “Print Your Certificate” will be available. You will also receive an email with the CME Certificate attached once the course is completed.     Read More

Overview There are many knowledge gaps in treating Upper Tract Urolhelial Cancer (UTUC), and one particularly important cause of the knowledge gaps is the relative rarity of UTUC. The fact is, many patients are seen by multiple different people, so there is generally not an assigned specialist for a specific patient. This creates a very diluted experience and few physicians have concentrated experience in treating UTUC. One of the major issues in treating UTUC is the difficulty in diagnosis and lack of appropriate risk stratification. That relates to both imaging challenges and endoscopic challenges in getting an adequate biopsy sample. Additionally, it is difficult to determine the stage of disease. Sometimes a biopsy showing low-grade disease sometimes is actually high-grade disease. We have risk stratification tools and risk calculators that do a better job of assessing disease. This helps determine whether it is possible to preserve a patient’s kidney or if more aggressive treatment like chemotherapy is required. Improved collaboration between the care team and improved physician education about best treatment practices and the importance of collaboration is important. However, these improvements would be best done in a systematic, methodical fashion. The goal of this 60-minute CME activity is to educate the medical community of how to identify, assess, and treat Upper Tract Urothelial Cancer (UTUC), and to improve outcomes for the patients being treated. Faculty Jennifer A. Linehan, MD Associate Professor of Urology and Urologic Oncology John Wayne Cancer Institute, Santa Monica, California Phillip M. Pierorazio, MD Associate Professor of Urologic Oncology James Buchanan Brady Urologic Institute John Hopkins Medicine, Baltimore, Maryland Course Director Surena F. Matin, MD, FACS Professor (with tenure), Department of Urology, Division of Surgery The University of Texas MD Anderson Cancer Center, Houston, Texas Accreditation This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Carden Jennings Publishing, Co., Ltd. MER is accredited by ACCME to provide continuing medical education for physicians. Medical Education Resources designates this live, online activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been accredited by Medical Education Resources for the following dates: Start date: 11/09/2020 End date: 11/09/2021 Format: enduring webcast This activity has been developed and is intended and designed for primary care physicians, urologists, and other healthcare providers involved in the treatment of patients with upper tract urothelial carcinoma. Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physician Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Carden Jennings Publishing, Co., Ltd. Credit Designation Statement Medical Education Resources designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. MER Policies on Commercial Support and Conflict of Interest Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest. This activity is jointly provided by Medical Education Resources and Carden Jennings Publishing Co., Ltd. This activity is supported by an education grant from UroGen Pharma Inc.  Individual disclosures are provided below.  Potential conflicts have been resolved through MER’s content review process. The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: Jennifer A. Linehan, MD  ​Consulting fee: Urogen, Initiative Surgical Speaker: Urogen​ Surena F. Matin, MD Consulting fee: QED Therapeutics, Urogen Phillip M Pierorazio, MD Grants/Research: Site PI, Olympus trial Consulting Fee: Scientific Advisory Board The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity: Carden Jennings Publishing No financial relationships to disclose MER content managers No financial relationships to disclose How to Complete the Course and Obtain CME Certificate This course is divided into three sections: Pre-Test Two presentations and a panel discussion Post-Test The pre-test will consist of 5 multiple-choice questions. Once the pre-test has been completed, select “Click Here to Continue” to advance to the lecture. After watching the entire lecture, select “Click Here to Continue” to advance to the post-test. The post-test will consist of 5 multiple-choice questions. Once the post-test has been completed, select “Click Here to Continue,” and you will be redirected to the course page, where the option to “Print Your Certificate” will be available. You will also receive an email with the CME Certificate attached once the course is completed.     Read More

The goal of this educational program is to equip urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in prostate cancer care with the up-to-date clinical knowledge and tools they need to best treat their patients. The program aims to provide a clinical update on aspects of diagnosis and treatment of localized and advanced disease. The content in this program came from the 24th Southwest Prostate Cancer Symposium, and this is a highlight of the conference. Program Faculty William K. Oh, MD Chief, Division of Hematology and Medical Oncology Deputy Director, Tisch Cancer Institute Professor of Medicine and Urology Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics Icahn School of Medicine at Mount Sinai New York, New York Daniel P. Petrylak, MD Professor of Medicine (Medical Oncology) and Urology Director, Prostate and GU Medical Oncology Director, Prostate Cancer Translational Research Group Yale Cancer Center New Haven, CT Target Audience This activity was developed and is intended primarily for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Needs Assessment Over the past three decades, researchers have found a number of treatments, including chemotherapies, anti-androgens, and androgen receptor blockers, that can be used in combination with androgen deprivation therapy to extend survival in patients with this disease.  Many therapeutic options are approved and used for mCRPC. However, fewer options exist for those with non-metastatic (nm) CRPC, also known as M0 prostate cancer. Fortunately, some recent studies on treating nmCRPC have shown promising results.  Faculty, Staff, and Planner’s Disclosures In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:   William K. Oh, MD, has provided the following disclosures:   Consultant for AstraZeneca; Bayer; CPS Companion Diagnostics; Janssen Biotech; Sanofi Genzyme; Sema4; TeneoBio; and Tyme, Inc.   Daniel P. Petrylak, MD, has provided the following disclosures:   Grant/Research Support: Agensys, AstraZeneca, Bayer, Clovis, Dendreon, Eli Lilly, Endocyte, Genentech, Innocrin, Janssen Biotech, MedImmune, Merck, Millennium, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Genzyme, Sotio; Consultant: AstraZeneca, Bayer, Bellicum, Dendreon, Exelixis, Ferring, Janssen Biotech, Millennium, Pfizer, Roche Laboratories, Sanofi Genzyme, Bellicum, Tyme, Inc.   The staff of CJP Medical Communications has no relevant financial relationships with commercial interests to disclose.   The staff of the Medical College of Wisconsin has no relevant financial relationships with commercial interests to disclose.   The educational content of this program has been peer-reviewed by The Medical College of Wisconsin. Disclaimer The material presented at or in any Medical College of Wisconsin or Carden Jennings Publishing Company, Ltd., continuing education activity does not necessarily reflect the views and opinions of Medical College of Wisconsin or Carden Jennings Publishing. Neither Medical College of Wisconsin nor Carden Jennings Publishing, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product. Support Information This activity is supported by an educational grant from Sanofi Genzyme. References: 1. Gietema JA, Oosting SF, Docetaxel for metastatic prostate cancer: Early is better. Ned Tijdschr Geneeskd. 2016;160:D215. 2. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PAF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomized, double-blind, placebo controlled phase 3 study. The Lancet Oncology. Feb 2015; 16(2): 152-160.  3. James N, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-351. 4. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377:352-360. 5. Scher HI, Fizazi K, Saad F, et al, for the AFFIRM Investigators. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012; 367:1187-1197. 6. Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. J Clin Onc 2019; 37: 687-687. 7. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. April  2018. N Engl J Med. 2018; 378:1408-1418.  8. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378:2465-2474.  9. Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer (ARAMIS). Orion Corporation, Orion Pharma and Bayer. July 2014 - [Cited 2018 Oct 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT02200614. NLM Identifier: NCT02200614. 10. James ND et al. ASCO 2015. Abstract 5001. Read More

Shopping Cart

Your cart is empty